Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Bone and Calcium Disorders
What is the recommended duration of Burosumab therapy for treating X-linked hypophosphatemia and how is response to therapy monitored?
Related Questions
In post-bariatric surgery patients presenting with secondary hyperparathyroidism, what is the optimal approach to assess calcium supplementation adequacy?
Would you start romosozumab in an active smoker?
Can a 60-year-old male have a bone density test showing a normal T-score but a low Z-score?
Would you offer bisphosphonate therapy for infants with osteogenesis imperfecta type 11?
Is there a target alkaline phosphatase level for hypophosphatasia patients on asfotase alfa therapy?
Do you routinely prescribe vitamin D to reduce the risk of fall-related fractures in elderly patients regardless of their serum levels?
What patient factors are most important when considering who needs a broader workup for osteoporosis prior to starting therapy?
Does parathyroidectomy for primary hyperparathyroidism provide metabolic benefits, such as lowering diabetes or cardiovascular disease risk?
Do patients with 25 OH vitamin D levels under 20 ng/ml and normal PTH levels ("relative hypoparathyroidism") still carry a risk for bone and calcium metabolism disorders such as osteomalacia?
How do you approach vitamin D supplementation in patients with chronic kidney disease, given the findings that vitamin D2 supplementation may lead to decreased conversion of 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3?
